Comparative analysis of the effects of nomegestrol acetate/17 β-estradiol and drospirenone/ethinylestradiol on premenstrual and menstrual symptoms and dysmenorrhea
Open Access
- 5 November 2014
- journal article
- research article
- Published by Taylor & Francis Ltd in The European Journal of Contraception & Reproductive Health Care
- Vol. 20 (4), 296-307
- https://doi.org/10.3109/13625187.2015.1016154
Abstract
To compare premenstrual and menstrual symptoms in healthy women using nomegestrol acetate/17β-estradiol (NOMAC/E2) and drospirenone/ethinylestradiol (DRSP/EE) via the Moos Menstrual Distress Questionnaire Form C (MDQ-C). Women completed the MDQ-C at baseline and after completion of cycles 1, 3, 6 and 13, for the premenstrual (four days before most recent flow) and menstrual (most recent flow) phases in two randomized controlled trials. Treatment effects of NOMAC/E2 and DRSP/EE on the t-scores of eight MDQ-C symptom domains from 3522 women were examined, and the effects of both treatments on the score for cramps from 1779 women with moderate to severe cramps at baseline. Longitudinal data analysis methods were applied in both analyses. NOMAC/E2 users experienced a significant improvement in Pain, Water Retention, Negative Affect, Impaired Concentration and Behaviour Change domain scores in the menstrual phase compared with DRSP/EE users (p < 0.001 for all comparisons). However, Arousal (emotional and mental) scores worsened with NOMAC/E2 but not with DRSP/EE. Women with moderate to severe cramps experienced an improvement in the cramps score with NOMAC/E2 and DRSP/EE. NOMAC/E2 was effective in reducing most premenstrual and menstrual symptoms, and was associated with significantly greater improvements in many MDQ-C domain scores compared with DRSP/EE. ( ClinicalTrials.gov: NCT00413062 and NCT00511199).Keywords
This publication has 24 references indexed in Scilit:
- Ethinyl estradiol and 17β-estradiol in combined oral contraceptives: pharmacokinetics, pharmacodynamics and risk assessmentContraception, 2013
- Nomegestrol acetate-17b-estradiol for oral contraceptionPatient Preference and Adherence, 2013
- Characteristics and metabolic effects of estrogen and progestins contained in oral contraceptive pillsBest Practice & Research Clinical Endocrinology & Metabolism, 2013
- Efficacy, Safety, and Tolerability of a Monophasic Oral Contraceptive Containing Nomegestrol Acetate and 17β-EstradiolObstetrics & Gynecology, 2012
- The pharmacology of nomegestrol acetateMaturitas, 2012
- Efficacy and tolerability of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol in a 24/4 regimen, in comparison to an oral contraceptive containing ethinylestradiol and drospirenone in a 21/7 regimenThe European Journal of Contraception & Reproductive Health Care, 2011
- Metabolic effects of contraceptive steroidsReviews in Endocrine and Metabolic Disorders, 2011
- Biological Effects of Estradiol-17β in Postmenopausal Women: Oral Versus percutaneous AdministrationJournal of Clinical Endocrinology & Metabolism, 1986
- Comparison of hepatic impact of oral and vaginal administration of ethinyl estradiolAmerican Journal of Obstetrics and Gynecology, 1985
- Comparison of pharmacodynamic properties of various estrogen formulationsAmerican Journal of Obstetrics and Gynecology, 1982